borderline significantP=0.08
In a separate STAMPEDE report establishing the benefit of Abiraterone in the ADT sensitive status ( 9 ), the subgroup analysis for FFS demonstrates a significant interaction for an increased benefit with planned EBRT (P=0.02) and borderline significant interaction with nonmetastatic patients (P=0.08).